Regulation - Asia-Pacific, Antibiotics and Infectious diseases


Popular Filters

Leading Chinese hepatitis B vaccine makers stop production; Pfizer drug import halted


China’s Food and Drug Administration announced on January 2 that the country’s three leading manufacturers…

Anti-viralsAntibiotics and Infectious diseasesAsia-PacificBioKangtaiChinaFluconazolePfizerPharmaceuticalRegulationVaccines

Venus gets GMP certifications from Ukraine


Indian R&D-based drugmaker Venus Remedies (BSE: 526953) has been able to gain a Good Manufacturing Practice…

Antibiotics and Infectious diseasesAsia-PacificEuropeMarkets & MarketingOncologyPharmaceuticalProductionRegulationVenus Remedies

BioAlliance Pharma pursues development plan for Loramyc in Japan through partner Sosei


French orphan oncology and supportive care specialist BioAlliance Pharma (Euronext Paris: BIO) says its…

Antibiotics and Infectious diseasesAsia-PacificBioAlliance PharmaLoramycOravigPharmaceuticalRegulationResearchSosei

Pharmaceutical majors unite in Japan to combat H. pylori


On August 31, nine pharmaceutical companies operating in Japan (Kyowa Hakko Kirin, Takeda Pharmaceutical,…

Antibiotics and Infectious diseasesAsia-PacificAstraZenecaGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

Regulatory briefs: Amitiza in Japan; Dificid in Canada; Eurartesim roll-out


Sucampo Pharmaceuticals (Nasdaq: SCMP) and Abbott Labs (NYSE: ABT) have received approval from the Ministry…

Abbott LaboratoriesAmitizaAntibiotics and Infectious diseasesAsia-PacificDificidEurartesimGastro-intestinalsMarkets & MarketingNorth AmericaOptimer PharmaceuticalsPharmaceuticalRegulationSigma-TauSucampoTropical diseases

Back to top